We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
VistaGen Up on Fast Track Designation for Anxiety Disorder Drug
Read MoreHide Full Article
VistaGen Therapeutics, Inc. (VTGN - Free Report) announced that the FDA has granted a Fast Track designation to its first-in-class neuroactive nasal spray PH94B for on-demand treatment of social anxiety disorder (SAD), also called social phobia. Following successful completion of the phase II study on PH94B, VistaGen is now planning for its phase III development.
The FDA provides a Fast Track designation to help the development and faster review of drugs, which treat serious and unmet medical conditions. Per the company, PH94B becomes the first drug candidate to be granted a Fast Track status by the regulatory agency for treating SAD.
Shares of VistaGen were up an impressive 44.6% following the announcement of the aforementioned news on Tuesday. However, the stock has plunged 58.7% so far this year against the industry’s increase of 6.1%.
VistaGen, a clinical-stage biopharmaceutical company, is developing differentiated new generation medications for central nervous system (CNS) diseases and disorders with high unmet need.
Apart from PH94B, the company’s clinical-stage pipeline candidates include AV-101 and PH10.
AV-101 is an NMDA (N-methyl-D-aspartate) receptor glycine site antagonist, which is being evaluated as an adjunctive treatment of major depressive disorder (MDD).
In November 2019, VistaGen announced disappointing results from the phase II ELEVATE study, which evaluated the safety, tolerability and efficacy of AV-101 as an adjunctive treatment in patients with MDD, who had an inadequate response to a stable dose of standard antidepressant therapy.
AV-101 is also being developed as a non-opioid treatment for chronic neuropathic pain and an oral therapy for dyskinesia associated with levodopa therapy for Parkinson’s disease and suicidal ideation.
Notably, PH10 is a novel, rapid-acting CNS neuroactive nasal spray, currently being developed for treating MDD.
Anika’s earnings estimates have moved 16% north for 2019 and 17.4% for 2020 over the past 60 days. The stock has soared 64.9% year to date.
Guardant Health’s loss per share estimates have narrowed 30.7% for 2019 and 8.5% for 2020 over the past 60 days. The stock has skyrocketed 95.1% so far this year.
Innoviva’s earnings estimates have been revised 18.7% upward for 2019 and 25.2% for 2020 over the past 60 days.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Image: Bigstock
VistaGen Up on Fast Track Designation for Anxiety Disorder Drug
VistaGen Therapeutics, Inc. (VTGN - Free Report) announced that the FDA has granted a Fast Track designation to its first-in-class neuroactive nasal spray PH94B for on-demand treatment of social anxiety disorder (SAD), also called social phobia. Following successful completion of the phase II study on PH94B, VistaGen is now planning for its phase III development.
The FDA provides a Fast Track designation to help the development and faster review of drugs, which treat serious and unmet medical conditions. Per the company, PH94B becomes the first drug candidate to be granted a Fast Track status by the regulatory agency for treating SAD.
Shares of VistaGen were up an impressive 44.6% following the announcement of the aforementioned news on Tuesday. However, the stock has plunged 58.7% so far this year against the industry’s increase of 6.1%.
VistaGen, a clinical-stage biopharmaceutical company, is developing differentiated new generation medications for central nervous system (CNS) diseases and disorders with high unmet need.
Apart from PH94B, the company’s clinical-stage pipeline candidates include AV-101 and PH10.
AV-101 is an NMDA (N-methyl-D-aspartate) receptor glycine site antagonist, which is being evaluated as an adjunctive treatment of major depressive disorder (MDD).
In November 2019, VistaGen announced disappointing results from the phase II ELEVATE study, which evaluated the safety, tolerability and efficacy of AV-101 as an adjunctive treatment in patients with MDD, who had an inadequate response to a stable dose of standard antidepressant therapy.
AV-101 is also being developed as a non-opioid treatment for chronic neuropathic pain and an oral therapy for dyskinesia associated with levodopa therapy for Parkinson’s disease and suicidal ideation.
Notably, PH10 is a novel, rapid-acting CNS neuroactive nasal spray, currently being developed for treating MDD.
Zacks Rank & Other Stocks to Consider
VistaGen currently carries a Zacks Rank #2 (Buy). Other top-ranked stocks in the biotech sector include Anika Therapeutics Inc. (ANIK - Free Report) , Guardant Health, Inc. (GH - Free Report) and Innoviva, Inc. (INVA - Free Report) , all sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Anika’s earnings estimates have moved 16% north for 2019 and 17.4% for 2020 over the past 60 days. The stock has soared 64.9% year to date.
Guardant Health’s loss per share estimates have narrowed 30.7% for 2019 and 8.5% for 2020 over the past 60 days. The stock has skyrocketed 95.1% so far this year.
Innoviva’s earnings estimates have been revised 18.7% upward for 2019 and 25.2% for 2020 over the past 60 days.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>